29 March 2019 | News
Tel Aviv Sourasky Medical Centre will conduct a safety and tolerability trial on OWC’s sublingual tablets for the treatment of chronic low back pain
OWC Pharmaceutical Research Corp., the company transforming cannabis into scientifically proven and clinically approved medical solutions, announces an agreement with the Tel Aviv Sourasky Medical centre Fund.
The medical centre will perform a single-dose, randomized crossover study to compare the safety, tolerability, and pharmacokinetics of OWC’s tablet with Buccal Sativex in healthy adult volunteers. The tablet is designed to provide rapid API uptake through buccal membranes and to be a substitute for patients being treated with medical cannabis by smoking.
OWC Pharmaceutical Research Corp. is focusing its efforts on developing cannabis-based therapeutic products and treatments, specifically designed for several medical conditions and diseases. The company’s solutions include a topical ointment to treat skin diseases, such as psoriasis, a sublingual disintegrating tablet to treat chronic pain, and a unique formulation aimed at treating multiple Myeloma, a cancer of the plasma cells found in bone marrow.
Mordechai Bignitz, CEO of OWC Pharmaceutical Research Corp. said, “There is a very large amount of hype surrounding medical applications of cannabis, but we are one of the few companies doing real medical research. Our collaboration with Sourasky Medical centre is further proof of our commitment to developing real cannabis-based medical solutions.”
OWC Pharmaceutical Research Corp. conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.